Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 5, 2007, Pages 651-660

  Guichard, S M ^a   Hua, M L ^a   Kang, P ^a   MacPherson, J S ^a   Jodrell, D I ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Apoptosis; Bcl xL siRNA; HCT 116; Senescence

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIMYCIN A3; CAMPTOTHECIN; CITRININ; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; IRINOTECAN; PROTEIN BCL 2; PROTEIN BCL XL; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL AGING; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; STATISTICAL SIGNIFICANCE; TUMOR XENOGRAFT;

ANIMALS; ANTIMYCIN A; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-X PROTEIN; CAMPTOTHECIN; CELL DEATH; COLONIC NEOPLASMS; DOWN-REGULATION; DOXORUBICIN; HCT116 CELLS; HUMANS; MICE; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34547842484     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0408-1     Document Type: Article

References (35)

1. Arriola EL, Rodriguez-Lopez AM, Hickman JA, Chresta CM (1999) Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene 18:1457
2. Backus HH, Van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, Pinedo HM, Peters GJ (2002) Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol 55:206
3. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 296:1000
4. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K, Roninson IB (1999) A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59:3761
5. Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J, Roninson IB (1999) Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18:4808
6. Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB (2002) Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci USA. 99:389
7. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27
8. Crescenzi E, Palumbo G, Brady HJ (2003) Bcl-2 activates a programme of premature senescence in human carcinoma cells. Biochem J 375:263
9. Dallas A, Vlassov AV (2006) RNAi: A novel antisense technology and its therapeutic potential. Med Sci Monit 12:RA67
10. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494
11. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI (2003) Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin Cancer Res 9:2856
12. Ho HK, Hu ZH, Tzung SP, Hockenbery DM, Fausto N, Nelson SD, Bruschi SA (2005) BCL-xL overexpression effectively protects against tetrafluoroethylcysteine-induced intramitochondrial damage and cell death. Biochem Pharmacol 69:147
13. Holt SE, Aisner DL, Shay JW, Wright WE (1997) Lack of cell cycle regulation of telomerase activity in human cells. Proc Natl Acad Sci USA. 94:10687
14. Kim R (2005) Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 333:336
15. Kim KM, Giedt CD, Basanez G, O'Neill JW, Hill JJ, Han YH, Tzung SP, Zimmerberg J, Hockenbery DM, Zhang KY (2001) Biophysical characterization of recombinant human Bcl-2 and its interactions with an inhibitory ligand, antimycin. A Biochemistry 40:4911
16. Letai A (2005) Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest 115:2648
17. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ (2004) Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6:241
18. Maurer CA, Friess H, Buhler SS, Wahl BR, Graber H, Zimmermann A, Buchler MW (1998) Apoptosis inhibiting factor Bcl-xL might be the crucial member of the Bcl-2 gene family in colorectal cancer. Dig Dis Sci 43:2641
19. Minderman H, Conroy JM, O'Loughlin KL, McQuaid D, Quinn P, Li S, Pendyala L, Nowak NJ, Baer MR (2005) In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther 4:885
20. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109:335
21. Shay JW, Roninson IB (2004) Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23:2919
22. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, Tsujimoto Y (2004) Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 6:1221
23. Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, Deckwirth T, Frost DJ, Jarvis K, Joseph MK, Marsh K, McClellan W, Nellans H, Ng S, Nimmer P, O'Connor JM, Oltersdorf T, Qing W, Shen W, Stavropoulos J, Tahir SK, Wang B, Warner R, Zhang H, Fesik SW, Rosenberg SH, Elmore SW (2006) A Small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 66:8731
24. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107
25. Tanaka R, Ariyama H, Qin B, Shibata Y, Takii Y, Kusaba H, Baba E, Mitsugi K, Harada M, Nakano S (2005) Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. Oncol Rep 14:683
26. te Poele RH, Joel SP (1999) Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. Br J Cancer 81:1285
27. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP (2002) DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62:1876
28. Tuschl T (2001) RNA interference and small interfering RNAs. Chembiochem 2:239
29. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, Zhang KY, Hockenbery DM (2001) Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 3:183
30. Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT, Thompson CB (1997) Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell 91:627
31. Vidal L, Blagden S, Attard G, de Bono J (2005) Making sense of antisense. Eur J Cancer 41:2812
32. Wang X, Zhang J, Kim HP, Wang Y, Choi AM, Ryter SW (2004) Bcl-XL disrupts death-inducing signal complex formation in plasma membrane induced by hypoxia/reoxygenation. Faseb J 18:1826
33. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, Liu JR (2005) Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 96:287
34. Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J, Escandon E (2002) Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. Oncogene 21:3611
35. Zhu H, Guo W, Zhang L, Davis JJ, Teraishi F, Wu S, Cao X, Daniel J, Smythe WR, Fang B (2005) Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 4:451